Loading clinical trials...
Loading clinical trials...
A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Aclidinium Bromide 200 µg
Aclidinium Bromide 400 µg
Locations
113
United States
Forest Investigative Site 1162
Birmingham, Alabama, United States
Forest Investigative Site 1127
Mobile, Alabama, United States
Forest Investigative Site 1475
Scottsdale, Arizona, United States
Forest Investigative Site 1338
Tempe, Arizona, United States
Forest Investigative Site 1349
Tucson, Arizona, United States
Forest Investigative Site 1483
Buena Park, California, United States
Start Date
November 1, 2009
Primary Completion Date
April 1, 2011
Completion Date
April 1, 2011
Last Updated
April 20, 2017
NCT05746039
NCT07190209
NCT07307781
NCT07073950
NCT07509606
NCT07451977
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions